Search
Pentoxifylline
go.drugbank.com/drugs/DB00806ApprovedInvestigational[A226608] Pentoxifylline has been marketed in Europe since 1972; PTX extended-release tablets sold under the trade name TRENTAL by US Pharm Holdings were first approved by the FDA on Aug 30, 1984, but … [A226415, L30300] Although originally developed to treat intermittent claudication, a form of exertion-induced leg pain common in patients with peripheral arterial disease, PTX has been investigated for
Categories: Drugs for Obstructive Airway Diseases, Compounds used in a research, industrial, or household settingArginine
go.drugbank.com/drugs/DB00125ApprovedInvestigationalNutraceuticalAn essential amino acid that is physiologically active in the L-form.
Mixtures: GLAMIN SOLUTION FOR INFUSION, KABIVEN EMULSION FOR INFUSIONCategories: Detoxifying Agents for Antineoplastic TreatmentPibrentasvir
go.drugbank.com/drugs/DB13878ApprovedInvestigationalIn combination with [DB13879], pibrentastiv is a useful therapy for patients who experienced therapeutic failure from other NS5A inhibitors. … Mavyret is also indicated for HCV genotype 1-infected patients who have been previously treated with regimens either containing an NS5A inhibitor or an NS3/4A protease inhibitor, but not both [L940].
Categories: Antivirals for Systemic Use, Antiinfectives for Systemic UseBaricitinib
go.drugbank.com/drugs/DB11817ApprovedInvestigational[L41760] Baricitinib was first approved by the European Commission (EC) in February 2017 for the treatment of rheumatoid arthritis in adults [A248395] and was later approved by the FDA in 2018. … [A248400] The EC later approved baricitinib for the treatment of atopic dermatitis, making it the first JAK inhibitor used for this indication in Europe.
Categories: Experimental Unapproved Treatments for COVID-19Lorlatinib
go.drugbank.com/drugs/DB12130ApprovedInvestigationalLorlatinib is a third-generation ALK tyrosine kinase inhibitor (TKI) for patients with ALK-positive metastatic non-small cell lung cancer[L39905] which was first approved by the US FDA in November of 2018 … It was subsequently approved by the EMA in 2019 for the treatment of select patients with previously treated advanced ALK-positive non-small cell lung cancer, followed by an expanded approval in 2022 to
Levonorgestrel
go.drugbank.com/drugs/DB00367ApprovedInvestigational[A181988,T659] Also known as Plan B, it is used as a single agent in emergency contraception, and as a hormonal contraceptive released from an intrauterine device, commonly referred to as an IUD.
Categories: Hormonal Contraceptives for Systemic UseMethionine
go.drugbank.com/drugs/DB00134ApprovedInvestigationalNutraceuticalIt is a chelating agent for heavy metals.
Mixtures: GLAMIN SOLUTION FOR INFUSION, KABIVEN EMULSION FOR INFUSIONSulfamethoxazole
go.drugbank.com/drugs/DB01015ApprovedInvestigational[L11830] In this combination, sulfamethoxazole is useful for the treatment of a variety of bacterial infections, including those of the urinary, respiratory, and gastrointestinal tracts. … which inhibits a sequential step in bacterial folic acid synthesis - these agents work synergistically to block two consecutive steps in the biosynthesis of nucleic acids and proteins which are necessary for
Mixtures: KEMOPRİM FORT 800/160 TABLET, SEPTRIN FORT TABLET, 20 ADETCategories: Antibacterials for Systemic Use, Antiinfectives for Systemic UseBezlotoxumab
go.drugbank.com/drugs/DB13140Approved[L46976] On November 22, 2016, the Committee for Medicinal Products for Human Use of the European Medicines Agency recommended the granting of a marketing authorization. … [A260106] The drug was granted full approval by the EMA on January 18, 2017.[L47191]
Categories: Antiinfectives for Systemic UseAncrod
go.drugbank.com/drugs/DB05099ApprovedWithdrawnFDA granted a 'fast-track status' for investigation of ancrod use in patients suffering from acute ischemic stroke, a life threatening condition caused by the blockage of blood vessels supplying blood … Currently, Viprinex®/ancrod is not approved or marketed in any country, but is being investigated as a stroke treatment in worldwide clinical trials. In January 2005, the U.S.